IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Clinical trial NCT04562129 · RECRUITING
Trial details
- NCT number
- NCT04562129
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-24
- Primary completion
- 2026-07-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.